FDA Approves Osimertinib for the Adjuvant Treatment of EGFRm NSCLC

On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent.

Read the FDA announcement.

Read AstraZeneca's announcement.

Posted 12/21/2020